Academy of Managed Care Pharmacy Annual Meeting 2026 (AMCP)

Back

Zeleciment Basivarsen Targets the Underlying Cause of Myotonic Dystrophy Type 1 (DM1) to Enable Functional Improvement in the Phase 1/2 ACHIEVE Trial (poster)

View

Zeleciment Rostudirsen Targets the Underlying Cause of Duchenne Muscular Dystrophy (DMD) to Enable Sustained Functional Improvement in Males with DMD Mutations Amenable to Exon 51 Skipping Enrolled in the Phase 1/2 DELIVER Trial (poster)

View

Health Insurance Profile and Literacy in Myotonic Dystrophy Type 1 (DM1) (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.